March 30, 2022, Ottawa – Canadian Blood Services’ contracts with suppliers of recombinant factor VIII and IX for the 2022-2025 period take effect on April...
by David Page, CHS National Director of Health Policy The Canadian Hemophilia Society (CHS), its chapters and members have expended great efforts to advocate for...
Updated charts for products in the pipeline have been uploaded on the CHS website. The CHS publishes four charts, one each for clotting factor concentrates, inhibitor...
by David Page, CHS National Director of Health Policy Access to a wide range of coagulation products is expanding in the provinces and territories served by...
Mild hemophilia can be very serious and even life-threatening if injuries or bleeds are not treated promptly and adequately. The past few years, a lot...